Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aon PLC (AON) vs Crispr Therapeutics AG (CRSP) Price & Performance

Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Aon PLC vs Crispr Therapeutics AG — how do they compare? Aon PLC trades at $356.48 (market cap $75.61B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: Aon PLC is far larger — about 14.5× Crispr Therapeutics AG's market cap, and Aon PLC pays a 0.92% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

AONCRSP
Market Cap
$75.61B$5.23B
Sector
FinancialsHealth
52-Week High
$381.26$76.78
52-Week Low
$308.22$44.34
Enterprise Value
$90.22B$3.65B
Dividend Yield
0.92%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aon PLC

Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.

Read more on AON

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP